China's Science Rise Is Becoming a Business Risk Issue

Why frontier research now matters for companies, not only governments and universities.

Charles Lieber's move from Harvard to Shenzhen is not just a story about one scientist. It is a story about where frontier research is being funded, equipped, and turned into national capability.

Reuters recently reported that Lieber, a former Harvard chemist and one of the world's leading brain-computer interface researchers, is now heading a state-funded institute in Shenzhen. He had previously been convicted in the United States for lying to federal investigators about China-linked payments and ties to a state talent recruitment programme. His new role gives him access to dedicated nanofabrication equipment and primate research facilities that were not available to him at Harvard. The sectors China is prioritising (brain-computer interfaces, artificial intelligence, semiconductors, biotechnology, advanced manufacturing, green energy) overlap directly with the technologies businesses depend on, compete with, source from, or may be restricted from accessing.

For much of the past decade, China's scientific rise was treated mainly as a research or policy issue: impressive metrics, geopolitical implications, but consequences that sat mostly in university strategy offices, government departments, and defence circles. That framing no longer holds. According to recent OECD data China's R&D spending has caught up with, and on purchasing-power measures slightly surpassed, that of the United States. China is not only increasing scientific output: it is connecting research capability to industrial policy, commercial ecosystems, and national strategy. This is the point at which a research story becomes a business risk story.

What this means for companies

For organisations operating across global markets, the consequences fall into several areas that are often managed separately. As China develops stronger capability across more technology layers, the landscape of what can be sourced, partnered, or co-developed changes continuously: a supplier, software dependency, or manufacturing process that looked commercially straightforward two years ago may carry a different risk profile today. The mechanisms by which research capability and technical knowledge move between countries are not always transparent, which matters in joint ventures, university partnerships, licensing, or R&D collaboration. The United States and its allies continue to expand controls on technology transfer; a company that maps its China exposure once and leaves that map unchanged is running a risk process that is already ageing. China's investment is also creating genuine new capability in sectors where it was not previously a leading force. For some companies that opens new suppliers, customers, or research opportunities, while for others it creates restrictions or market-entry risks. Often, both at once.

This matters most for companies exposed to advanced manufacturing, medical technology, AI, semiconductors, energy transition supply chains, research partnerships, export-controlled goods, or China-linked suppliers and customers. But the perimeter is wider than many organisations draw it. A company does not need to operate a lab in Shenzhen to be affected. It may depend on components developed in China, suppliers using Chinese technology, research collaborations involving Chinese institutions, or products increasingly viewed through a national security lens.

The structural gap

Most organisations have some form of China risk posture. Fewer have a China technology risk posture, and fewer still have one dynamic enough to track the current rate of change. China's science rise does not arrive as a single discrete event. It develops through accumulating signals: a five-year plan designation, a new research institute, a talent recruitment case, an export control update, a supplier shift, a university partnership that carries different implications than it would have a few years ago. Standard risk processes tend to underweight exactly this kind of slow-moving structural change until the exposure becomes acute.

China's science rise has been a long-running story. It is now also an operational reality. The question for most companies is not whether it affects them. It is whether they have thought through where and how, and what they will do about it.

ES Advisors supports organisations in turning complex and emerging risk into clear, actionable decisions.